Impetigo - Pipeline Review, H1 2016 Summary Global Markets Direct's, 'Impetigo - Pipeline Review, H1 2016', provides an overview of the Impetigo pipeline landscape. The report provides comprehensive information on the therapeutics under development for Impetigo, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Impetigo and features dormant and discontinued projects. Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis. The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data. Scope - The report provides a snapshot of the global therapeutic landscape of Impetigo - The report reviews pipeline therapeutics for Impetigo by companies and universities/research institutes based on information derived from company and industry-specific sources - The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages - The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved Impetigo therapeutics and enlists all their major and minor projects - The report assesses Impetigo therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type - The report summarizes all the dormant and discontinued pipeline projects - The report reviews latest news related to pipeline therapeutics for Impetigo Reasons To Buy - Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Identify and understand important and diverse types of therapeutics under development for Impetigo - Identify potential new clients or partners in the target demographic - Develop strategic initiatives by understanding the focus areas of leading companies - Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics - Devise corrective measures for pipeline projects by understanding Impetigo pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and Scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Table of Contents
Table of Contents 2 List of Tables 4 List of Figures 5 Introduction 6 Global Markets Direct Report Coverage 6 Impetigo Overview 7 Therapeutics Development 8 Pipeline Products for Impetigo - Overview 8 Pipeline Products for Impetigo - Comparative Analysis 9 Impetigo - Therapeutics under Development by Companies 10 Impetigo - Therapeutics under Investigation by Universities/Institutes 11 Impetigo - Pipeline Products Glance 12 Late Stage Products 12 Clinical Stage Products 13 Early Stage Products 14 Impetigo - Products under Development by Companies 15 Impetigo - Products under Investigation by Universities/Institutes 16 Impetigo - Companies Involved in Therapeutics Development 17 Foamix Pharmaceuticals Ltd. 17 Laboratories Ojer Pharma S.L. 18 Lytix Biopharma AS 19 Toyama Chemical Co., Ltd. 20 Impetigo - Therapeutics Assessment 21 Assessment by Monotherapy Products 21 Assessment by Target 22 Assessment by Mechanism of Action 24 Assessment by Route of Administration 26 Assessment by Molecule Type 28 Drug Profiles 30 FMX-102 - Drug Profile 30 Product Description 30 Mechanism of Action 30 R&D Progress 30 LTX-109 - Drug Profile 31 Product Description 31 Mechanism of Action 31 R&D Progress 31 mupirocin - Drug Profile 33 Product Description 33 Mechanism of Action 33 R&D Progress 33 ozenoxacin - Drug Profile 34 Product Description 34 Mechanism of Action 34 R&D Progress 34 Synthetic Peptides for Infectious Disease - Drug Profile 36 Product Description 36 Mechanism of Action 36 R&D Progress 36 Impetigo - Recent Pipeline Updates 37 Impetigo - Dormant Projects 39 Impetigo - Discontinued Products 40 Impetigo - Product Development Milestones 41 Featured News & Press Releases 41 Jun 12, 2014: Medimetriks Pharmaceuticals Announces that the Second Phase III Study for Ozenoxacin has been Initiated by Ferrer 41 Jun 05, 2013: Ferrer Completes Phase III Clinical Trial Of Ozenoxacin In Adult And Pediatric Patients With Impetigo 41 Feb 22, 2013: Lytix Biopharma Enrolls First Patient In LTX-109 Phase II Proof Of Concept Infection Study 42 Oct 05, 2012: Ferrer Successfully Completes Absorption, Tolerability And Safety Study In Juveniles As Young As Two Months Of Age For New Antibacterial Compound Ozenoxacin 43 Jan 19, 2012: Ferrer Initiates Phase III Clinical Studies For Ozenoxacin In Development As Topical Treatment For Impetigo And Other Infectious Dermatological Conditions 43 Appendix 45 Methodology 45 Coverage 45 Secondary Research 45 Primary Research 45 Expert Panel Validation 45 Contact Us 45 Disclaimer 46
List of Tables
Number of Products under Development for Impetigo, H1 2016 8 Number of Products under Development for Impetigo - Comparative Analysis, H1 2016 9 Number of Products under Development by Companies, H1 2016 10 Number of Products under Investigation by Universities/Institutes, H1 2016 11 Comparative Analysis by Late Stage Development, H1 2016 12 Comparative Analysis by Clinical Stage Development, H1 2016 13 Comparative Analysis by Early Stage Development, H1 2016 14 Products under Development by Companies, H1 2016 15 Products under Investigation by Universities/Institutes, H1 2016 16 Impetigo - Pipeline by Foamix Pharmaceuticals Ltd., H1 2016 17 Impetigo - Pipeline by Laboratories Ojer Pharma S.L., H1 2016 18 Impetigo - Pipeline by Lytix Biopharma AS, H1 2016 19 Impetigo - Pipeline by Toyama Chemical Co., Ltd., H1 2016 20 Assessment by Monotherapy Products, H1 2016 21 Number of Products by Stage and Target, H1 2016 23 Number of Products by Stage and Mechanism of Action, H1 2016 25 Number of Products by Stage and Route of Administration, H1 2016 27 Number of Products by Stage and Molecule Type, H1 2016 29 Impetigo Therapeutics - Recent Pipeline Updates, H1 2016 37 Impetigo - Dormant Projects, H1 2016 39 Impetigo - Discontinued Products, H1 2016 40
List of Figures
Number of Products under Development for Impetigo, H1 2016 8 Number of Products under Development for Impetigo - Comparative Analysis, H1 2016 9 Number of Products under Development by Companies, H1 2016 10 Assessment by Monotherapy Products, H1 2016 21 Number of Products by Targets, H1 2016 22 Number of Products by Stage and Targets, H1 2016 22 Number of Products by Mechanism of Actions, H1 2016 24 Number of Products by Stage and Mechanism of Actions, H1 2016 24 Number of Products by Routes of Administration, H1 2016 26 Number of Products by Stage and Routes of Administration, H1 2016 26 Number of Products by Molecule Types, H1 2016 28 Number of Products by Stage and Molecule Types, H1 2016 28
Global LCP (Liquid Crystal Polymer) industry is forecasted to reach USD 1.23 billion by 2020, as per a new research report by Radiant Insights, Inc. Growing trend towards developing militarized components and connectors are likely to drive the demandRead More...
Global fluorotelomers market size is anticipated to be valued at USD 539.3 million by 2020, as per a new research report by Radiant Insights, Inc. Increasing application scope in fire fighting systems owing to growing safety concerns is likely to driRead More...
Global outsourced customer care services market is projected to reach USD 84.7 billion by 2020, as per a new research report by Radiant Insights, Inc. Swelling need for interaction through non-voice channels is estimated to boost global demand over tRead More...
Global aquafeed market size is anticipated to be valued at USD 165.04 billion by 2022, as per a new research report by Radiant Insights, Inc. Increase in fish consumption for direct and indirect consumer applications is anticipated to drive the markeRead More...
Global activated carbon market size is likely to be valued at USD 5.3 billion by 2020; as per a new research report by Radiant Insights, Inc. Increase in commercial & residential waste water treatment demand owing to escalation in water prices is antRead More...
Get your queries resolved from an industry expert. Request for a free product review before report purchase.
Toll Free: 1-888-928-9744
Email: [email protected]
Speak to the report author to design an exclusive study to serve your research needs.
A testimonial for service excellence represented in the form of BBB "A" Accreditation.
Your personal and confidential information is safe and secure.